{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:29:28Z","timestamp":1792578568707,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.msard.2022.104436","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T01:21:51Z","timestamp":1669598511000},"page":"104436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Volumetric brain changes in MOGAD: A cross-sectional and longitudinal comparative analysis"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-9783","authenticated-orcid":false,"given":"Itay","family":"Lotan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibo","family":"Billiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemie","family":"Ribbens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Hecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Kister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104436_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103170","article-title":"Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls","volume":"55","author":"Alvarez","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.104436_bib0036","article-title":"Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis","volume":"7","author":"Barnes","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1-2","key":"10.1016\/j.msard.2022.104436_bib0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jns.2006.08.017","article-title":"Inflammatory demyelination and neurodegeneration in early multiple sclerosis","volume":"259","author":"Charil","year":"2007","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2022.104436_bib0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"issue":"21","key":"10.1016\/j.msard.2022.104436_bib0031","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2022.104436_bib0004","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1212\/NXI.0000000000000543","article-title":"Cranial nerve involvement in patients with MOG antibody-associated disease","volume":"6","author":"Cobo-Calvo","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.104436_bib0003","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2022.104436_bib0021","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/jnnp-2020-324826","article-title":"Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS","volume":"92","author":"Duan","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2022.104436_bib0041","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1212\/NXI.0000000000000229","article-title":"Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD","volume":"3","author":"Finke","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.104436_bib0010","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.msard.2022.104436_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577653","article-title":"Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: A review","volume":"358","author":"Gombolay","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2022.104436_bib0042","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3389\/fneur.2020.01045","article-title":"Brain atrophy rates for stable multiple sclerosis patients on long-term fingolimod versus glatiramer acetate","volume":"11","author":"Honce","year":"2020","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104436_bib0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ene.13224","article-title":"Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"24","author":"Hyun","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.104436_bib0028","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nicl.2015.05.003","article-title":"Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images","volume":"8","author":"Jain","year":"2015","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.msard.2022.104436_bib0030","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3389\/fnins.2016.00576","article-title":"Two time point MS lesion segmentation in brain MRI: an expectation-maximization framework","volume":"10","author":"Jain","year":"2016","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.msard.2022.104436_bib0002","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammat."},{"issue":"7","key":"10.1016\/j.msard.2022.104436_bib0017","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00415-016-8138-8","article-title":"Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder","volume":"263","author":"Jeong","year":"2016","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.104436_bib0005","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.msard.2022.104436_bib0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2022.104436_bib0025","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010403","article-title":"Progressive brain atrophy and white matter changes in MOG encephalomyelitis","author":"Kwon","year":"2020","journal-title":"Neurology"},{"issue":"1-2","key":"10.1016\/j.msard.2022.104436_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jns.2006.08.016","article-title":"Multiple sclerosis: is there neurodegeneration independent from inflammation?","volume":"259","author":"Lassmann","year":"2007","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.msard.2022.104436_bib0037","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/14737175.2021.1982697","article-title":"Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review","volume":"21","author":"Lin","year":"2021","journal-title":"Expert. Rev. Neurother."},{"issue":"14","key":"10.1016\/j.msard.2022.104436_bib0014","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1212\/WNL.0000000000001441","article-title":"Differential patterns of spinal cord and brain atrophy in NMO and MS","volume":"84","author":"Liu","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2022.104436_bib0001","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104436_bib0044","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/jnnp-2021-326386","article-title":"Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Masuda","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2022.104436_bib0023","article-title":"Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis","author":"Messina","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104436_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577702","article-title":"Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder","volume":"360","author":"Molazadeh","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.msard.2022.104436_bib0018","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/jnnp-2018-318382","article-title":"Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study","volume":"89","author":"Oertel","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2022.104436_bib0019","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001068","article-title":"Retinal optical coherence tomography in neuromyelitis optica","volume":"8","author":"Oertel","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"10","key":"10.1016\/j.msard.2022.104436_bib0040","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/jnnp-2018-320249","article-title":"Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders","volume":"90","author":"Papadopoulou","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2022.104436_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2021.102608","article-title":"Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: a longitudinal study","volume":"30","author":"Papadopoulou","year":"2021","journal-title":"Neuroimage Clin."},{"issue":"2","key":"10.1016\/j.msard.2022.104436_bib0035","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000665","article-title":"MS optic neuritis-induced long-term structural changes within the visual pathway","volume":"7","author":"Pawlitzki","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"10","key":"10.1016\/j.msard.2022.104436_bib0016","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1177\/1352458519861603","article-title":"Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography","volume":"26","author":"Pisa","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104436_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awac030","article-title":"Anterior optic pathway pathology in CNS demyelinating diseases","author":"Pisa","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.msard.2022.104436_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2021.102707","article-title":"icobrain ms 5.1: combining unsupervised and supervised approaches for improving the detection of multiple sclerosis lesions","volume":"31","author":"Raki\u0107","year":"2021","journal-title":"Neuroimage Clin."},{"issue":"2","key":"10.1016\/j.msard.2022.104436_bib0033","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2018","journal-title":"Nature Rev. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.104436_bib0007","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0000000000003542","article-title":"Brain MRI atrophy quantification in MS: From methods to clinical application","volume":"88","author":"Rocca","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104436_bib0046","doi-asserted-by":"crossref","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD","author":"Salama","year":"2020","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2022.104436_bib0008","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41582-020-0314-x","article-title":"MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice","volume":"16","author":"Sastre-Garriga","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2022.104436_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.499910","article-title":"Differences in advanced magnetic resonance imaging in MOG-IgG and AQP4-IgG seropositive neuromyelitis optica spectrum disorders: a comparative study","volume":"11","author":"Schmidt","year":"2020","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.104436_bib0047","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012467","article-title":"Comparison of MRI lesion evolution in different central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2022.104436_bib0039","doi-asserted-by":"crossref","first-page":"691","DOI":"10.14336\/AD.2016.0419","article-title":"Thalamic Atrophy Contributes to Low Slow Wave Sleep in Neuromyelitis Optica Spectrum Disorder","volume":"7","author":"Su","year":"2016","journal-title":"Aging Dis."},{"key":"10.1016\/j.msard.2022.104436_bib0038","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/brain\/awv396","article-title":"Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis","volume":"139","author":"Tur","year":"2016","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.msard.2022.104436_bib0012","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2022.104436_bib0024","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1177\/1352458520964415","article-title":"Brain structural and functional alterations in MOG antibody disease","volume":"27","author":"Zhuo","year":"2021","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2022.104436_bib0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/01.wnl.0000316810.01120.05","article-title":"Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis","volume":"71","author":"Zivadinov","year":"2008","journal-title":"Neurology"},{"issue":"1-2","key":"10.1016\/j.msard.2022.104436_bib0026","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jns.2005.03.006","article-title":"Steroids and brain atrophy in multiple sclerosis","volume":"233","author":"Zivadinov","year":"2005","journal-title":"J. Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:09:48Z","timestamp":1761901788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822009403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":47,"alternative-id":["S2211034822009403"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104436","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Volumetric brain changes in MOGAD: A cross-sectional and longitudinal comparative analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104436"}}